drugset / Trial / NCT00919607

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

NCT00919607

Phase 1 Completed 31 enrolled AstraZeneca
RandomizedSingle-groupOpen-label

Summary

The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .

Timeline

Start
2009-06
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 200 mg Oral
Subject Quetiapine Small molecule 300 mg Oral
Subject Quetiapine Small molecule 600 mg Oral
Subject Quetiapine Small molecule 800 mg Oral

Indications